OneSource Specialty Pharma, a newly incorporated Contract Development and Manufacturing Organisation (CDMO), formed from the merger of three CDMO businesses within the Bangalore -based Strides Group was launched at the recently concluded CPHI Milan – an annual pharma industry exhibition. The company has a 30-year track-record in biologics, drug-device combinations, and soft gelatin capsules.
The newly combined CDMO has five facilities approved by major regulatory agencies, including the US FDA, EU, and TGA, with a workforce of over 1,200 professionals. OneSource has capabilities spanning supply-constrained drug-device combinations, biologics, and soft gelatin capsules – with the capacity to produce more than 100 million injectable doses including cartridges and pre-filled-syringes and 2.4 billion soft gelatin capsules. Its flagship site in Bangalore is one of the few globally capable of manufacturing both biologics drug substance and drug product on the same premises.
The three combined businesses, each serve over 50 global clients, and together reduce complexity, cost, and resources associated with managing multiple CDMO service providers.
OneSource is projected to achieve 32% revenue growth in 2025, with sales anticipated to reach $400-mn by 2028. The company's strong growth prospects are driven by industry trends, including the increasing self-administration of drugs via auto-injectors, led by significant success of GLP-1 medications. In addition, the US Biosecure Act is continuing to drive significant interest as pharma partners look to increase supply chain diversity and security, and serves as a tailwind to the CDMO's ambitious growth plans.
Mr. Neeraj Sharma, CEO of OneSource, stated, "As demand for innovative CDMO solutions grows, especially for complex therapies, we are well-positioned to accelerate drug development and manufacturing for our global partners."
Strides Pharma had sought shareholder approval for a scheme of arrangement among the company, Steriscience Specialties Pvt Ltd and Onesource Specialty Pvt Ltd (earlier known as Stelis Biopharma). As part of the scheme, Strides Pharma and Steriscience's identified CDMO business, along with Strides Pharma' soft gelatine business, would be consolidated under Onesource.
OneSource is currently undergoing regulatory approvals and, upon completion, will be listed on Indian stock exchanges.


15 October, 2024 12:24:12 IST 
















